Background An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage III, …

Background Most patients with locally advanced, unresectable, non–small-cell lung cancer (NSCLC)
have disease progression despite definitive chemoradiotherapy (chemotherapy …

PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with
unresectable, stage III non–small-cell lung cancer and no disease progression after …

Background Standard first-line therapy for metastatic, squamous non–small-cell lung cancer
(NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with …

Introduction In the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable,
stage III NSCLC without disease progression after concurrent chemoradiotherapy, …

… Vicente reports receiving honoraria (self/spouse) for scientific advice or as a speaker from
AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, and …

Introduction In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC
without progression after chemoradiotherapy, durvalumab demonstrated significant …

Importance Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as
monotherapies or in combination with anti–cytotoxic T-lymphocyte–associated antigen 4 …

The primary analysis of the global, randomized, phase III KEYNOTE-407 study demonstrated
significantly improved overall survival (OS) and progression-free survival (PFS) with …

8511 Background: In the placebo-controlled Phase III PACIFIC trial of patients with unresectable
Stage III NSCLC whose disease had not progressed after platinum-based concurrent …